A*STAR Infectious Diseases Labs (A*STAR IDL)

Researchers pinpoint a specific marker for gastric cancer stem cells and show that eliminating this subpopulation may be a viable approach to more effectively treat stomach cancers.

A molecule found in Aedes mosquito saliva modulates the host body’s immune response during chikungunya infection, highlighting that mosquitoes may be more than just viral carriers.

A*STAR researchers uncover how bacterial hideouts created during tuberculosis infections can also protect and feed other opportunistic invaders.

Region-specific stem cells may not only act as starting points for colorectal cancer, but also offer new clues for early detection and treatment.

As the Chairman of Singapore’s lead R&D public sector agency, Chorh Chuan Tan outlines A*STAR’s strategic role within a new phase of national strategic priorities in research, innovation and enterprise.

A unique RNA structure shared across SARS-CoV-2 variants may contribute to viral fitness, offering a potential target for new antiviral treatments.

An anti-hypertension drug could potentially be repurposed as a more affordable treatment for liver cancer.

Whether combating global viral threats or advancing next-generation telecommunications, the A*STAR winners of the 2025 President’s Science and Technology Awards showcase the talent and drive at the foundations of world-class research excellence.

In recognition of their research excellence, leadership and impact both locally and globally, ten leading A*STAR researchers have been awarded the A*STAR Distinguished Fellowship and Fellowships.

A new ‘liquid lipid’ approach that penetrates the nose’s mucus barrier could lead to needle-free, nasal spray-based mRNA vaccines.

This year, the National Research Foundation Singapore is empowering three A*STAR researchers to push the boundaries of science.

Researchers uncovered how specialised stem cells act as building blocks for the esophagus, shaping its development and offering insights into treating related diseases.